Pharma and Biopharma Outsourcing Solutions from Intertek - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma and Biopharma Outsourcing Solutions from Intertek

Intertek, a leading provider of Pharmaceutical Services will highlight how its unique blend of expert pharmaceutical & biopharmaceutical analysis, auditing and regulatory services are helping to save the industry material costs whilst raising the safety of its products and reliability of its supply chains at ICSE / CPhi, Madrid, Spain, 9-11 October 2012. Stand 10E89.

In particular Intertek’s service offering for biologics will be a key focus area. With the annual sales of biologic drugs forecast to grow up to three times faster than conventional drugs over the next 5 years Intertek’s strategy has been to establish a “one stop” analytical shop specifically relating to the requirements of ICH Q6B. The team, based in UK, Ireland, Basel and Sand Diego specializes in the design and delivery of regulatory (GXP) studies relating to the physiochemical and biological activity of biomolecules, bioanalytical support and manufacturing troubleshooting.

Experts from Intertek Pharmaceutical Services will be available during ICSE to share the experience of its history of successful innovative and tailored programmes. Covering a wide scope of services for both clinical development and product testing, such as GLP bioanalysis, GMP product analysis, auditing, method development validation and remediation, GMP microbiology, manufacturing technical support or sustainability consultancy, Intertek experts will be engaging on clients’ outsourcing needs for the year ahead and beyond.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
FindPharma Custom Search

Click here